Welcome to our dedicated page for Nexalin Tech news (Ticker: NXLIW), a resource for investors and traders seeking the latest updates and insights on Nexalin Tech stock.
Nexalin Technology, Inc. develops non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology for brain-health and mental-health indications. Company news centers on clinical evidence for its neurostimulation platform, including peer-reviewed studies involving insomnia, depression-related symptoms, traumatic brain injury, PTSD, Alzheimer’s disease, dementia-related cognitive decline and ADHD.
Updates also cover the HALO™ Clarity headset, the NeuroCare® virtual clinic platform, collaborations with clinical research and academic organizations, FDA De Novo strategy, international regulatory activity, and public-company events affecting Nexalin securities.
Nexalin (NASDAQ: NXL) reported a peer-reviewed BMC Psychiatry pilot showing 21 days of 77.5 Hz, 15 mA DIFS stimulation in six female adolescents with non‑suicidal self‑injury produced statistically significant reductions in depressive symptoms and self‑injury scores.
Changes in TMS‑EEG functional connectivity across Default, Limbic, Salience/Ventral Attention and Control networks were reported; authors call results preliminary and recommend larger randomized trials.
Nexalin (Nasdaq: NXL) announced a planned pivotal, randomized, triple-blinded, sham-controlled 150‑participant trial of HALO™ Clarity for moderate-to-severe insomnia to support a planned de novo submission to the U.S. FDA. The fully decentralized study uses Nexalin’s NeuroCare virtual clinic and EDC, runs four weeks of treatment plus four weeks follow-up, and is conducted with Lindus Health.
The program builds on a prior 120‑participant randomized, double‑blind, placebo‑controlled study published in the Journal of Psychiatric Research and on Nexalin’s Gen‑2 15 mA device regulatory approvals internationally.
Nexalin (Nasdaq: NXL) praised recent bipartisan Congressional actions increasing federal support for deep brain neurostimulation research and said its DIFS™ technology aligns with emerging VA and NIH priorities.
The company noted two appropriations reports signed into law supporting neuromodulation research and an ongoing UC San Diego/San Diego VA study of DIFS™, while H.R. 7091 remains under committee review.
Nexalin (Nasdaq:NXL) launched NeuroCare®, an AI-designed virtual clinic integrated with its new Gen-3 HALO™ headset to deliver home-based Deep Intracranial Frequency Stimulation (DIFS™).
The platform, deployed initially with UC San Diego, supports remote physician monitoring, subscription billing, and clinical trial enrollment for Alzheimer’s, mood disorders, TBI and PTSD.
Nexalin (Nasdaq: NXL) highlighted a growing peer-reviewed neuroimaging literature supporting its Deep Intracranial Frequency Stimulation (DIFS™) as a non-invasive approach that modulates deep brain networks across mood, military, and memory indications.
Key studies include a randomized, double-blind, sham-controlled trial showing objective gamma‑frequency normalization via MEG/EEG and multiple fMRI/PET reports linking network changes to clinical improvement.
Nexalin Technology (Nasdaq: NXL) received a Nasdaq notification dated January 21, 2026 stating it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) after 30 consecutive business days below the $1.00 bid threshold. The company has been granted 180 calendar days, until July 20, 2026, to regain compliance by achieving a closing bid of at least $1.00 for a minimum of 10 consecutive trading days. Shares will continue to trade uninterrupted under ticker NXL. The company said it will monitor the bid price and is considering measures to improve its financial position; it is not considering a reverse stock split at this time.
Nexalin Technology (Nasdaq: NXL) announced a peer‑reviewed, randomized double‑blind sham‑controlled trial published in Molecular Psychiatry showing four weeks of its non‑invasive DIFS™ neurostimulation improved attention and normalized brain activity in adults with ADHD.
In 56 adults, active treatment produced a 10.1‑point average improvement on the Adult ADHD Self‑Report Scale versus 5.5‑points for sham (4.6‑point separation, p < 0.001), plus MEG/EEG evidence of reduced excessive gamma activity and restored network communication. Treatment was well tolerated with no serious adverse events reported.
Nexalin Technology (NASDAQ: NXL) completed a substantive FDA Q-Submission meeting for its Gen-2 SYNC™ neurostimulation console targeting mild-to-moderate Alzheimer’s disease on December 3, 2025. The FDA provided a clear framework for Nexalin’s planned U.S. Pilot Study and discussed a potential De Novo classification pathway.
FDA and Nexalin aligned on pilot and pivotal trial design elements, patient population, dosing paradigm, statistical plan, and primary/secondary endpoints including cognitive tests, PET, blood biomarkers, and functional imaging. Company will use feedback for its U.S. IDE submission.
Nexalin Technology (Nasdaq: NXL) invites investors to a live webinar on December 4, 2025 at 4:15 p.m. ET hosted by RedChip Companies.
CEO Mark White will discuss Nexalin’s proprietary non-invasive Deep Intracranial Frequency Stimulation (DIFS™), recent clinical collaborations including UC San Diego, the Gen-3 HALO™ Clarity headset, and a Virtual Clinic model for scalable at-home treatment. The company says it has secured regulatory approvals internationally while pursuing U.S. expansion and targets the $537 billion mental health market. Management will highlight patented technology, real-time AI-driven patient monitoring, and global footprint growth, followed by a live Q&A. Registration is free at the RedChip webinar page and questions can be pre-submitted to NXL@redchip.com.
Nexalin Technology (Nasdaq: NXL) reported a peer-reviewed case report in The American Journal on Addictions showing promising results using its 15 mA neurostimulation device to treat gambling disorder comorbid with alcohol use disorder.
In a single patient treated at Shanghai Mental Health Center, 20 outpatient sessions over 10 days (15 mA at 77.5 Hz for 40 minutes each) produced complete abstinence from gambling and alcohol, improved cognitive control, and no adverse effects during a three-month follow-up. The study (ClinicalTrials.gov NCT06195995) received ethics approval. The device is approved in China for depression and insomnia. Authors recommend larger controlled trials to confirm findings.